OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease

by Business Wire • 2022/10/19 • 0 Comments

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces the publication of a paper featuring Phase 1b data on OTT166 in OSLI Retina.